CD274 and head and neck squamous cell carcinoma: Recently, in a phase I/II trial, enoblituzumab (anti-B7-H3 antibody) combined with pembrolizumab in post-platinum PD-L1-naive recurrent/metastatic HNSCC showed 33% of patients to experience ORR (131).